**MATE- altrenogest solution**
**Aurora Pharmaceutical, Inc.**

---

## Mate Oral Progestagen for Horses

2.2 mg/mL altrenogest

For regulation and control of the breeding cycle of mares
• To induce ovulatory oestrus early in the breeding season in mares where some follicular activity exists
• For the suppression of oestrus either during prolonged oestrus or in normally cycling mares
• For the control of the ovarian cycle in breeding mares to allow the most efficient use of the stallion

For the maintenance of pregnancy in habitually aborting mares, or mares at risk of early embryonic death or abortion, where progesterone deficiency is thought to be the underlying cause.

**Read the carton for full instruction**

**DIRECTIONS FOR USE**

**Restraints:**
**DO NOT USE on male animals.**

**Contraindications:**
Contraindicated for use in mares suffering from uterine infections.

**Precautions:**
Use with caution as unused feed must be destroyed and not given to any other animals. MATE must be added to the feed immediately prior to consumption and not stored.

**Dosage and Administration:**

For oral administration.
Administer 1 mL MATE per 50 kg bodyweight (equivalent to 0.044 mg altrenogest per kg) daily.
1. Regulation and control of the breeding cycle of mares
a. For the induction of ovulatory oestrus or to induce cyclical ovarian activity in mares with some follicle activity early in the breeding season: Administer MATE daily for 10 consecutive days.
b. For the suppression of oestrus in normally cycling mares: Administer MATE daily for 15 consecutive days. For the suppression of prolonged oestrus: Administer MATE daily for 10 consecutive days.
c. To control the breeding cycle of mares to allow efficient use of the stallion: Administer MATE daily for 15 consecutive days.
2. For the treatment of habitually aborting mares, or mares at risk of early embryonic death or abortion: Administer MATE daily, from the 2nd or 3rd day after ovulation in the mated or inseminated mare, continuing until day 120 of gestation.

NOTE: Ultrasound scanning to confirm pregnancy is recommended on day 14 or 15

after ovulation. If the mare is not pregnant, it is advised to cease MATE administration and to administer an injection of prostaglandin F2α to destroy any luteal tissue that may be still present, allowing the mare to return to oestrus and be re-mated.

**MEAT WITHHOLDING PERIODS (HORSES)**

**DO NOT USE less than 28 days before slaughter for human consumption.**

**SAFETY DIRECTIONS**

Product is harmful if absorbed by skin contact, inhaled or swallowed. Avoid contact with eyes and skin. Do not inhale. When using the product wear rubber gloves. After use and before eating, drinking or smoking, wash hands, arms and face thoroughly with soap and water. After each day's use, wash gloves. Care should be taken to avoid contact between the solution and women of child bearing age.

**FIRST AID INSTRUCTIONS**
If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 13 11 26.

**ADDITIONAL USER SAFETY INFORMATION**
Additional information is listed in the safety data sheet (SDS).

**STORAGE**

Store below 25°C (air conditioning). Protect from light.

Manufactured by:
Aurora Pharmaceutical, Inc.

Distributed by:
South Yarra Pharma Pty Ltd
27-33 Piper Line, East Bendigo VIC 3550
Australia
Call Toll-free: 1800 426 142

APVMA Approval No.: 92068/134364

PRINCIPAL DISPLAY PANEL - 1000 mL bottle label

IN 50-1715 06/2023




# MATE

altrenogest solution

| Product Information | | | |
|---|---|---|---|
| **Product Type** | PRESCRIPTION ANIMAL DRUG | **Item Code (Source)** | NDC:51072-119 |
| **Route of Administration** | ORAL | | |

| Active Ingredient/Active Moiety | | |
|---|---|---|
| **Ingredient Name** | **Basis of Strength** | **Strength** |
| **ALTRENOGEST** (UNII: 2U0X0JA2NB) (ALTRENOGEST - UNII:2U0X0JA2NB) | ALTRENOGEST | 2.2 mg in 1 mL |

| Product Characteristics | | | |
|---|---|---|---|
| **Color** | yellow (colorless to yellow) | **Score** | |
| **Shape** | | **Size** | |
| **Flavor** | | **Imprint Code** | |
| **Contains** | | | |

| Packaging | | | | |
|---|---|---|---|---|
| **#** | **Item Code** | **Package Description** | **Marketing Start Date** | **Marketing End Date** |
| **1** | NDC:51072-119-00 | 1000 mL in 1 BOTTLE | | |

## Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|---|---|---|---|
| export only | | 09/01/2023 | |

## Labeler - Aurora Pharmaceutical, Inc. (832848639)

## Establishment

| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Aurora Pharmaceutical, Inc. | | 832848639 | manufacture |

Revised: 9/2023 Aurora Pharmaceutical, Inc.